| 1 |
Siegel R, Ma J, Zou Z, et al. Cancer statisics,2014[J]. CA Cancer J Clin,2014,64(1): 9-29.doi: 10.3322/caac.21208. |
| 2 |
Chen W, Zheng R, Zheng S, et al. Report of incidence and mortlity in China cancer registries，2009[J]. Chin JCancer Res，2013，25(1):10-21.doi: 10.3978/j.issn.1000-9604.2012.12.04. |
| 3 |
|
| 4 |
Duquette M, Sadou PM, Lawler J, et al. Thrombospondin-1 sliencing down-regulates integrin expressing levels in human anaplastic thyroid cancer cells with BRAF(V600E): new insights in the host tissue adaptation and homeostasis of tumormicroenviroment[J]. Front Endocrinol(Lausanne),2013,4:189.doi: 10.3389/fendo.2013.00189. |
| 5 |
阿勒哈，孟庆彬，于健春，等. 甲状腺癌分子发展机制研究[J].中国医学科学院学报，2013，35(4):382-385.
|
| 6 |
Catalano MG, Fortunati N, Boccuzzi G, et al.Epigenetics modification and therapeutic propects in human thyroid cancer[J].Front Endocrinol(Lausanne),2012,3:40.doi: 10.3389/fendo.2012.00040. |
| 7 |
Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primany and metastatic radioactive iodine-refractory thyroid cancers receals distinct pathogenetic roles for BRAF,PIK3CA, and AKT1[J]. Cancer Res,2009,69(11)4885-4893.doi: 10.1158/0008-5472.CAN-09-0727. |
| 8 |
Smallridge RC, Marlow LA, Copland JA, et al.Anaplastics thyroid cancer:molecular pathogenesis and emerging therapies[J].EndocrRelat Cancer,2009,16(1):17-44.doi: 10.1677/ERC-08-0154. |
| 9 |
Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancer[J]. EndocrRelat Cancer,2013,20(4):603-610.dio: 10.1530/ERC-13-0210. |
| 10 |
Pennell NA, Daniels GH, Haddad RI, et al.A phase II study of gefitinib in patients with advanced thyroid cancer[J]. Thyriod,2008,18(3):317-323.
|
| 11 |
Masago K, Miuro M, Toyama Y, et al. Good clinical response to erlotinib in a patient with anaplastic thyroid cancinoma harboring an epidermal growth factor somatic mutation,L858R, in exon 21[J].J ClinOncol,2011, 29(16):e465-e467.doi: 10.1200/JCO.2010.34.0216. |
| 12 |
Hogan T, Jing JY, Williams HJ, et al.Oncocytic, focally anaplastic thyroid cancer responding to erlotinib[J]. J Oncol Pharm Pract,2009,15(2):1111-117.doi: 10.1177/1078155208101212. |
| 13 |
Ha HT, Lee JS, Urba S, et al.A phase II study of imatinib in patients with advanced anaplastic tyyriodcancer[J].Thriod,2010,20(9):975-980.doi: 10.1089/yhy.2010.0057. |
| 14 |
杨朝旭，孙飘扬，秦叔逵. 小分子VEGFR-2酪氨酸激酶抑制剂阿帕替尼对肝癌细胞的抑制作用及其机制的研究[C]. 全国临床肿瘤学大会暨CSCO学术年会, 2012.
|
| 15 |
Tian S, Quan HT, Xie CY, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo [J]. Cancer Sci, 2011, 102(7): 1374-1380.doi: 10.1111/j.1349-7006.2011.01939.x. |
| 16 |
Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J]. BMC Cancer, 2010, 10: 529.doi: 10.1186/1471-2407-10-529. |